Diagnostic and Prognostic Value of Plasma lncRNA SRA1 in Chronic Heart Failure

Diagnostic and Prognostic Value of Plasma lncRNA SRA1 in Chronic Heart Failure

Blog Article

Background: The pathogenesis and development of chronic heart failure (CHF) may involve long non-coding ribonucleic acid (lncRNA) steroid receptor RNA activator 1 (SRA1), a known cardiomyopathy risk factor and regulator of cardiac myofibroblast activation.This study aimed to investigate the application of SRA1 in the early detection and prediction of CHF.Methods: SRA1 plasma expression was determined in CHF patients and healthy individuals/using real time-quantitative polymerase chain reaction (RT-qPCR).The diagnostic and prognostic value of SRA1 was assessed using receiver operating curve (ROC) and Cox Spring Pulley regression analyses.

Results: Compared with the healthy controls, the patients with CHF had increased brain natriuretic peptide (BNP) levels, left atrial end-systolic diameter (LAD), left ventricular end-diastolic diameter (LVDd), and decreased left ventricular ejection fraction (LVEF).SRA1 was significantly upregulated in CHF patients as well as positively correlated with BNP Hydro 4 Parts level, LAD, and LVDd, and negatively correlated with LVEF.SRA1 could sensitively discriminate CHF patients from healthy individuals and was an independent predictor of adverse event-free survival in CHF patients.Conclusions: Upregulated plasma SRA1 can discriminate patients with CHF from healthy individuals and predict adverse outcomes in CHF patients.

Thus, SRA1 is a potential molecular indicator for monitoring chronic heart failure development.